BACKGROUND: The live attenuated dengue virus type 4 (DEN-4) vaccine candidate virus rDEN4 Delta 30 was previously found to be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu). METHODS: In a follow-up placebo-controlled phase 2 clinical trial, rDEN4 Delta 30 was administered as a single inoculation to 3 separate dose cohorts (10(3) pfu, 10(2) pfu, or 10(1) pfu), for further evaluation. Each dose cohort consisted of 20 vaccinees and 4 placebo recipients. Volunteers were monitored closely for adverse events, and serum was collected on study days 28 and 42 for determination of neutralizing antibody titer. RESULTS: The vaccine was well tolerated at all doses studied. The most common adverse events observed were a transient asymptomatic rash in >50% of vaccinees and a mild neutropenia in approximately 20% of vaccinees. No vaccinee developed a dengue-like illness. The vaccine was highly infectious and immunogenic, with 95%-100% of vaccinees in each dose cohort developing a >/=4-fold increase in titers of serum neutralizing antibodies against DEN-4. CONCLUSIONS: The rDEN4 Delta 30 vaccine is safe and induced an antibody response that was broadly neutralizing against genotypically diverse DEN-4 viruses. It is a promising vaccine candidate for inclusion in a tetravalent dengue vaccine formulation.
RCT Entities:
BACKGROUND: The live attenuated dengue virus type 4 (DEN-4) vaccine candidate virus rDEN4 Delta 30 was previously found to be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu). METHODS: In a follow-up placebo-controlled phase 2 clinical trial, rDEN4 Delta 30 was administered as a single inoculation to 3 separate dose cohorts (10(3) pfu, 10(2) pfu, or 10(1) pfu), for further evaluation. Each dose cohort consisted of 20 vaccinees and 4 placebo recipients. Volunteers were monitored closely for adverse events, and serum was collected on study days 28 and 42 for determination of neutralizing antibody titer. RESULTS: The vaccine was well tolerated at all doses studied. The most common adverse events observed were a transient asymptomatic rash in >50% of vaccinees and a mild neutropenia in approximately 20% of vaccinees. No vaccinee developed a dengue-like illness. The vaccine was highly infectious and immunogenic, with 95%-100% of vaccinees in each dose cohort developing a >/=4-fold increase in titers of serum neutralizing antibodies against DEN-4. CONCLUSIONS: The rDEN4 Delta 30 vaccine is safe and induced an antibody response that was broadly neutralizing against genotypically diverse DEN-4 viruses. It is a promising vaccine candidate for inclusion in a tetravalent dengue vaccine formulation.
Authors: G William Letson; Pratap Singhasivanon; Eduardo Fernandez; Nihal Abeysinghe; Juan Jose Amador; Harold S Margolis; Robert Edelman Journal: Hum Vaccin Date: 2010-10-01
Authors: Maria G Guzman; Scott B Halstead; Harvey Artsob; Philippe Buchy; Jeremy Farrar; Duane J Gubler; Elizabeth Hunsperger; Axel Kroeger; Harold S Margolis; Eric Martínez; Michael B Nathan; Jose Luis Pelegrino; Cameron Simmons; Sutee Yoksan; Rosanna W Peeling Journal: Nat Rev Microbiol Date: 2010-12 Impact factor: 60.633
Authors: Anna P Durbin; Alexander Schmidt; Dan Elwood; Kimberli A Wanionek; Janece Lovchik; Bhavin Thumar; Brian R Murphy; Stephen S Whitehead Journal: J Infect Dis Date: 2010-12-14 Impact factor: 5.226
Authors: Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead Journal: J Infect Dis Date: 2013-01-17 Impact factor: 5.226
Authors: Peter F Wright; Sharon Ankrah; Susan E Henderson; Anna P Durbin; Jim Speicher; Stephen S Whitehead; Brian R Murphy; Alexander G Pletnev Journal: Vaccine Date: 2008-01-04 Impact factor: 3.641
Authors: Kathryn A Hanley; Mathilde Guerbois; Tiffany F Kautz; Meredith Brown; Stephen S Whitehead; Scott C Weaver; Nikos Vasilakis; Preston A Marx Journal: Am J Trop Med Hyg Date: 2014-08-04 Impact factor: 2.345
Authors: Julie H McArthur; Anna P Durbin; Jennifer A Marron; Kimberli A Wanionek; Bhavin Thumar; Dennis J Pierro; Alexander C Schmidt; Joseph E Blaney; Brian R Murphy; Stephen S Whitehead Journal: Am J Trop Med Hyg Date: 2008-11 Impact factor: 2.345
Authors: Scott A Smith; Ruklanthi de Alwis; Nurgun Kose; Anna P Durbin; Stephen S Whitehead; Aravinda M de Silva; James E Crowe Journal: J Infect Dis Date: 2013-03-22 Impact factor: 5.226
Authors: Anna P Durbin; Peter F Wright; Amber Cox; Wangeci Kagucia; Daniel Elwood; Susan Henderson; Kimberli Wanionek; Jim Speicher; Stephen S Whitehead; Alexander G Pletnev Journal: Vaccine Date: 2013-08-19 Impact factor: 3.641